{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:26:02Z","timestamp":1793676362402,"version":"4.5.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ministero della Salute"],"award-info":[{"award-number":["Ministero della Salute"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s00259-026-08173-x","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T01:57:26Z","timestamp":1789091846000},"page":"8543-8557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Baseline serum carcinoembryonic antigen (CEA) is an independent prognostic biomarker for metastatic castration-resistant prostate cancer (mCRPC) patients receiving 177Lu-PSMA therapy"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5383-4469","authenticated-orcid":false,"given":"Emilio Francesco","family":"Giunta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Foca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Celli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Caroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sarnelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Brighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Schepisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Monti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Lolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Sansovini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"8173_CR1","unstructured":"https:\/\/www.cancer.org\/cancer\/prostate-cancer\/detection-diagnosis-staging\/survival-rates.html"},{"issue":"2","key":"8173_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/ncpendmet0399","volume":"3","author":"JB Engel","year":"2007","unstructured":"Engel JB, Schally AV. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab. 2007;3(2):157\u201367.","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"12","key":"8173_CR3","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Prostate Cancer Clinical Trials Working Group 3, et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34(12):1402\u201318.","journal-title":"J Clin Oncol"},{"key":"8173_CR4","doi-asserted-by":"publisher","first-page":"100962","DOI":"10.1016\/j.drup.2023.100962","volume":"68","author":"M Cai","year":"2023","unstructured":"Cai M, Song XL, Li XA, Chen M, Guo J, Yang DH, Chen Z, Zhao SC. Current therapy and drug resistance in metastatic castration-resistant prostate cancer. Drug Resist Updat. 2023;68:100962.","journal-title":"Drug Resist Updat"},{"key":"8173_CR5","doi-asserted-by":"crossref","unstructured":"Wright GL Jr, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol. 1995;(1):18\u201328.","DOI":"10.1016\/1078-1439(95)00002-Y"},{"issue":"7","key":"8173_CR6","doi-asserted-by":"publisher","first-page":"950","DOI":"10.2967\/jnumed.118.223099","volume":"60","author":"L Emmett","year":"2019","unstructured":"Emmett L, Yin C, Crumbaker M, Hruby G, Kneebone A, Epstein R, et al. Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial 68Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade. J Nucl Med. 2019;60(7):950\u20134.","journal-title":"J Nucl Med"},{"issue":"12","key":"8173_CR7","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.3390\/biomedicines10123020","volume":"10","author":"S van der Gaag","year":"2022","unstructured":"van der Gaag S, Bartelink IH, Vis AN, Burchell GL, Oprea-Lager DE, Hendrikse H. Pharmacological Optimization of PSMA-Based Radioligand Therapy. Biomedicines. 2022;10(12):3020.","journal-title":"Biomedicines"},{"issue":"5","key":"8173_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3892\/etm.2024.12514","volume":"27","author":"T Niu","year":"2024","unstructured":"Niu T, Fan M, Lin B, Gao F, Tan B, Du X. Current clinical application of lutetium\u2013177 in solid tumors (Review). Exp Ther Med. 2024;27(5):225.","journal-title":"Exp Ther Med"},{"issue":"1","key":"8173_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2967\/jnumed.116.183194","volume":"58","author":"K Rahbar","year":"2017","unstructured":"Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Sch\u00e4fers M, Essler M, et al. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. J Nucl Med. 2017;58(1):85\u201390.","journal-title":"J Nucl Med"},{"key":"8173_CR10","doi-asserted-by":"publisher","first-page":"175883592311576","DOI":"10.1177\/17588359231157632","volume":"15","author":"A Jang","year":"2023","unstructured":"Jang A, Kendi AT, Sartor O. Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials. Ther Adv Med Oncol. 2023;15:17588359231157632.","journal-title":"Ther Adv Med Oncol"},{"issue":"12","key":"8173_CR11","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, et al. VISION Investigators. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091\u2013103.","journal-title":"N Engl J Med"},{"issue":"10276","key":"8173_CR12","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797\u2013804.","journal-title":"Lancet"},{"key":"8173_CR13","doi-asserted-by":"publisher","first-page":"S1324","DOI":"10.1016\/j.annonc.2023.10.085","volume":"34","author":"O Sartor","year":"2023","unstructured":"Sartor O, Gauna DC, Herrmann K, de Bono JS, Shore ND, Chi KNN, et al. LBA13 Phase III trial of [177Lu] Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore). Ann Oncol. 2023;34:S1324\u20135.","journal-title":"Ann Oncol"},{"issue":"5","key":"8173_CR14","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","volume":"25","author":"L Emmett","year":"2024","unstructured":"Emmett L, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, Weickhardt A, ENZA-p Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group, et al. [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2024;25(5):563\u201371.","journal-title":"Lancet Oncol"},{"key":"8173_CR15","unstructured":"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pluvicto-metastatic-castration-resistant-prostate-cancer"},{"key":"8173_CR16","doi-asserted-by":"publisher","first-page":"102699","DOI":"10.1016\/j.ctrv.2024.102699","volume":"125","author":"EF Giunta","year":"2024","unstructured":"Giunta EF, Brighi N, Gurioli G, Matteucci F, Paganelli G, De Giorgi U. 177Lu-PSMA therapy in metastatic prostate cancer: An updated review of prognostic and predictive biomarkers. Cancer Treat Rev. 2024;125:102699.","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"8173_CR17","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.euo.2022.05.003","volume":"5","author":"S Fanti","year":"2022","unstructured":"Fanti S, Briganti A, Emmett L, Fizazi K, Gillessen S, Goffin K, et al. EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy. Eur Urol Oncol. 2022;5(5):530\u20136.","journal-title":"Eur Urol Oncol"},{"issue":"61","key":"8173_CR18","doi-asserted-by":"publisher","first-page":"103108","DOI":"10.18632\/oncotarget.21600","volume":"8","author":"H Ahmadzadehfar","year":"2017","unstructured":"Ahmadzadehfar H, Schlolaut S, Fimmers R, Yordanova A, Hirzebruch S, Schlenkhoff C, Gaertner FC, Awang ZH, Hauser S, Essler M. Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy. Oncotarget. 2017;8(61):103108\u201316.","journal-title":"Oncotarget"},{"issue":"5","key":"8173_CR19","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00259-018-4236-4","volume":"46","author":"B Grubm\u00fcller","year":"2019","unstructured":"Grubm\u00fcller B, Senn D, Kramer G, Baltzer P, D\u2019Andrea D, Grubm\u00fcller KH, et al. Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46(5):1063\u201372.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"8173_CR20","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1097\/RLU.0000000000004222","volume":"47","author":"D Has Simsek","year":"2022","unstructured":"Has Simsek D, Kuyumcu S, Karadogan S, Ozkan ZG, Isik EG, Basaran M, Sanli MO, Sanli Y. Outcome of 177 Lu-PSMA Radionuclide Treatment in Advanced Prostate Cancer and Its Association With Clinical Parameters: A Single-Center Experience. Clin Nucl Med. 2022;47(8):e521\u20138.","journal-title":"Clin Nucl Med"},{"issue":"14","key":"8173_CR21","first-page":"1351","volume":"83","author":"J Stangl-Kremser","year":"2023","unstructured":"Stangl-Kremser J, Sun M, Ho B, Thomas J, Nauseef JT, Osborne JR, Molina A, Sternberg CN, Nanus DM, Bander NH, Tagawa S. Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy. Prostate. 2023;83(14):1351\u20137.","journal-title":"Prostate"},{"issue":"1","key":"8173_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s00259-017-3848-4","volume":"45","author":"K Rahbar","year":"2018","unstructured":"Rahbar K, Boegemann M, Yordanova A, Eveslage M, Sch\u00e4fers M, Essler M, Ahmadzadehfar H. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and\/or enzalutamide. A retrospective analysis of overall survival. Eur J Nucl Med Mol Imaging. 2018;45(1):12\u20139. https:\/\/doi.org\/10.1007\/s00259-017-3848-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"8173_CR23","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1007\/s00259-020-04723-z","volume":"47","author":"J Ferdinandus","year":"2020","unstructured":"Ferdinandus J, Violet J, Sandhu S, Hicks RJ, Ravi Kumar AS, Iravani A, et al. Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. Eur J Nucl Med Mol Imaging. 2020;47(10):2322\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"8173_CR24","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1007\/s00259-022-05853-2","volume":"49","author":"PE Hartrampf","year":"2022","unstructured":"Hartrampf PE, Seitz AK, Weinzierl FX, Serfling SE, Schirbel A, Rowe SP, K\u00fcbler H, Buck AK, Werner RA. Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up. Eur J Nucl Med Mol Imaging. 2022;49(12):4262\u201370.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"8173_CR25","doi-asserted-by":"publisher","first-page":"312","DOI":"10.2967\/jnumed.116.178228","volume":"58","author":"J Ferdinandus","year":"2017","unstructured":"Ferdinandus J, Eppard E, Gaertner FC, K\u00fcrpig S, Fimmers R, Yordanova A, Hauser S, Feldmann G, Essler M, Ahmadzadehfar H. Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617. J Nucl Med. 2017;58(2):312\u20139.","journal-title":"J Nucl Med"},{"issue":"11","key":"8173_CR26","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.2967\/jnumed.120.241588","volume":"61","author":"T Derlin","year":"2020","unstructured":"Derlin T, Werner RA, Lafos M, Henkenberens C, von Klot CAJ, Sommerlath Sohns JM, Ross TL, Bengel FM. Neuroendocrine Differentiation and Response to PSMA-Targeted Radioligand Therapy in Advanced Metastatic Castration-Resistant Prostate Cancer: A Single-Center Retrospective Study. J Nucl Med. 2020;61(11):1602\u20136.","journal-title":"J Nucl Med"},{"issue":"13","key":"8173_CR27","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","volume":"19","author":"AM Aparicio","year":"2013","unstructured":"Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013;19(13):3621\u201330. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3791.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"8173_CR28","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1007\/s00259-025-07661-w","volume":"53","author":"I Marini","year":"2026","unstructured":"Marini I, Giunta EF, Nicolini S, Grassi I, Foca F, Sarnelli A, et al. Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II study. Eur J Nucl Med Mol Imaging. 2026;53(5):3023\u201333. https:\/\/doi.org\/10.1007\/s00259-025-07661-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"8173_CR29","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12916-020-01817-1","volume":"18","author":"MA Cupp","year":"2020","unstructured":"Cupp MA, Cariolou M, Tzoulaki I, Aune D, Evangelou E, Berlanga-Taylor AJ. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med. 2020;18(1):360.","journal-title":"BMC Med"},{"key":"8173_CR30","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3389\/fphar.2016.00376","volume":"7","author":"C Lolli","year":"2016","unstructured":"Lolli C, Caffo O, Scarpi E, Aieta M, Conteduca V, Maines F, et al. Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone. Front Pharmacol. 2016;7:376.","journal-title":"Front Pharmacol"},{"issue":"7","key":"8173_CR31","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1158\/1055-9965.EPI-14-0146","volume":"23","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1204\u201312.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"7","key":"8173_CR32","doi-asserted-by":"publisher","first-page":"e0158770","DOI":"10.1371\/journal.pone.0158770","volume":"11","author":"J Cao","year":"2016","unstructured":"Cao J, Zhu X, Zhao X, Li XF, Xu R. Neutrophil-to-Lymphocyte Ratio Predicts PSA Response and Prognosis in Prostate Cancer: A Systematic Review and Meta-Analysis. PLoS ONE. 2016;11(7):e0158770.","journal-title":"PLoS ONE"},{"issue":"40","key":"8173_CR33","doi-asserted-by":"publisher","first-page":"e12504","DOI":"10.1097\/MD.0000000000012504","volume":"97","author":"J Wang","year":"2018","unstructured":"Wang J, Zhou X, He Y, Chen X, Liu N, Ding Z, Li J. Prognostic role of platelet to lymphocyte ratio in prostate cancer: A meta-analysis. Med (Baltim). 2018;97(40):e12504.","journal-title":"Med (Baltim)"},{"issue":"4","key":"8173_CR34","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"8173_CR35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","volume":"25","author":"MS Hofman","year":"2024","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Buteau JP, Joshua AM, et al. Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol. 2024;25(1):99\u2013107. https:\/\/doi.org\/10.1016\/S1470-2045(23)00529-6.","journal-title":"Lancet Oncol"},{"issue":"11","key":"8173_CR36","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.annonc.2025.07.003","volume":"36","author":"K Fizazi","year":"2025","unstructured":"Fizazi K, Chi KN, Shore ND, Herrmann K, de Bono JS, Castellano D, et al. PSMAfore Investigators. Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2025;36(11):1319\u201330. https:\/\/doi.org\/10.1016\/j.annonc.2025.07.003.","journal-title":"Ann Oncol"},{"issue":"3","key":"8173_CR37","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S1470-2045(25)00009-9","volume":"26","author":"L Emmett","year":"2025","unstructured":"Emmett L, Subramaniam S, Crumbaker M, Joshua AM, Sandhu S, Nguyen A, et al. Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2025;26(3):291\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(25)00009-9.","journal-title":"Lancet Oncol"},{"issue":"1","key":"8173_CR38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.6004\/jnccn.2022.7070","volume":"21","author":"D Mehrens","year":"2023","unstructured":"Mehrens D, Kramer KKM, Unterrainer LM, Beyer L, Bartenstein P, Froelich MF, et al. Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer. J Natl Compr Canc Netw. 2023;21(1):43\u2013e502.","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"8173_CR39","first-page":"3877","volume":"10","author":"D Dai","year":"2018","unstructured":"Dai D, Han S, Li L, Guo Y, Wei Y, Jin H, Wang X. Anemia is associated with poor outcomes of metastatic castration-resistant prostate cancer, a systematic review and meta-analysis. Am J Transl Res. 2018;10(12):3877\u201386.","journal-title":"Am J Transl Res"},{"issue":"4","key":"8173_CR40","doi-asserted-by":"publisher","first-page":"e402","DOI":"10.1016\/j.clgc.2019.12.002","volume":"18","author":"K Mori","year":"2020","unstructured":"Mori K, Janisch F, Mostafaei H, Lysenko I, Karakiewicz PI, Enikeev DV, Briganti A, Kimura S, Egawa S, Shariat SF. Prognostic Value of Hemoglobin in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. Clin Genitourin Cancer. 2020;18(4):e402\u20139.","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"8173_CR41","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1038\/s41598-023-29634-5","volume":"13","author":"Y Hakozaki","year":"2023","unstructured":"Hakozaki Y, Yamada Y, Takeshima Y, Taguchi S, Kawai T, Nakamura M, Iwaki T, Teshima T, Kinoshita Y, Akiyama Y, Sato Y, Yamada D, Suzuki M, Kume H. Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients. Sci Rep. 2023;13(1):2672.","journal-title":"Sci Rep"},{"key":"8173_CR42","unstructured":"Nalesnik JG, Mysliwiec AG, Canby-Hagino E. Anemia in men with advanced prostate cancer: incidence, etiology, and treatment. Rev Urol. 2004 Winter;6(1):1\u20134."},{"key":"8173_CR43","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.2147\/CMAR.S174237","volume":"10","author":"D Li","year":"2018","unstructured":"Li D, Lv H, Hao X, Hu B, Song Y. Prognostic value of serum alkaline phosphatase in the survival of prostate cancer: evidence from a meta-analysis. Cancer Manag Res. 2018;10:3125\u201339.","journal-title":"Cancer Manag Res"},{"key":"8173_CR44","doi-asserted-by":"crossref","unstructured":"Bitting RL, Armstrong AJ. Potential predictive biomarkers for individualizing treatment for men with castration-resistant prostate cancer. Cancer J 2013;19(1):25\u201333.","DOI":"10.1097\/PPO.0b013e31827e0b9c"},{"issue":"2","key":"8173_CR45","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10147-019-01578-9","volume":"25","author":"K Mori","year":"2020","unstructured":"Mori K, Janisch F, Parizi MK, Mostafaei H, Lysenko I, Enikeev DV, et al. Prognostic value of alkaline phosphatase in hormone-sensitive prostate cancer: a systematic review and meta-analysis. Int J Clin Oncol. 2020;25(2):247\u201357.","journal-title":"Int J Clin Oncol"},{"issue":"12","key":"8173_CR46","doi-asserted-by":"publisher","first-page":"e0307826","DOI":"10.1371\/journal.pone.0307826","volume":"19","author":"T Zhang","year":"2024","unstructured":"Zhang T, Li W, Wei H, Huang Z, Yang J, Zeng H, et al. Prognostic value of baseline alkaline phosphatase of 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis. PLoS ONE. 2024;19(12):e0307826.","journal-title":"PLoS ONE"},{"key":"8173_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-007-7681-4_13","volume-title":"Biomarkers in Cancer. Biomarkers in Disease: Methods, Discoveries and Applications","author":"J Li","year":"2015","unstructured":"Li J, Armstrong AJ. Prognostic and Predictive Biomarkers for Castration Resistant Prostate Cancer. In: Preedy V, Patel V, editors. Biomarkers in Cancer. Biomarkers in Disease: Methods, Discoveries and Applications. Dordrecht: Springer; 2015. https:\/\/doi.org\/10.1007\/978-94-007-7681-4_13."},{"issue":"2","key":"8173_CR48","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1006\/scbi.1998.0119","volume":"9","author":"S Hammarstr\u00f6m","year":"1999","unstructured":"Hammarstr\u00f6m S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol. 1999;9(2):67\u201381.","journal-title":"Semin Cancer Biol"},{"issue":"4\u20135","key":"8173_CR49","first-page":"191","volume":"1","author":"B Herbeth","year":"1980","unstructured":"Herbeth B, Bagrel A. A study of factors influencing plasma CEA levels in an unselected population. Oncodev Biol Med. 1980;1(4\u20135):191\u20138.","journal-title":"Oncodev Biol Med"},{"issue":"6","key":"8173_CR50","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3393\/ac.2019.11.13","volume":"35","author":"C Hall","year":"2019","unstructured":"Hall C, Clarke L, Pal A, Buchwald P, Eglinton T, Wakeman C, Frizelle F. A Review of the Role of Carcinoembryonic Antigen in Clinical Practice. Ann Coloproctol. 2019;35(6):294\u2013305.","journal-title":"Ann Coloproctol"},{"issue":"2","key":"8173_CR51","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1177\/108155899804600211","volume":"46","author":"JA Feuer","year":"1998","unstructured":"Feuer JA, Lush RM, Venzon D, Duray P, Tompkins A, Sartor O, Figg WD. Elevated carcinoembryonic antigen in patients with androgen-independent prostate cancer. J Investig Med. 1998;46(2):66\u201372.","journal-title":"J Investig Med"},{"issue":"13","key":"8173_CR52","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/pros.24400","volume":"82","author":"AW Bray","year":"2022","unstructured":"Bray AW, Duan R, Malalur P, Drusbosky LM, Gourdin TS, Hill EG, Lilly MB. Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration-resistant prostate cancer. Prostate. 2022;82(13):1264\u201372.","journal-title":"Prostate"},{"issue":"11","key":"8173_CR53","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1158\/1078-0432.CCR-13-3309","volume":"20","author":"H Beltran","year":"2014","unstructured":"Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, et al. Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res. 2014;20(11):2846\u201350.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"8173_CR54","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12149-023-01874-5","volume":"38","author":"K Michalski","year":"2024","unstructured":"Michalski K, Kosmala A, Werner RA, Serfling SE, Seitz AK, Lapa C, Buck AK, Hartrampf PE. Comparison of PET\/CT-based eligibility according to VISION and TheraP trial criteria in end-stage prostate cancer patients undergoing radioligand therapy. Ann Nucl Med. 2024;38(2):87\u201395.","journal-title":"Ann Nucl Med"},{"issue":"8","key":"8173_CR55","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/bjc.1998.635","volume":"78","author":"E Baudin","year":"1998","unstructured":"Baudin E, Gigliotti A, Ducreux M, Ropers J, Comoy E, Sabourin JC, Bidart JM, Cailleux AF, Bonacci R, Ruffi\u00e9 P, Schlumberger M. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer. 1998;78(8):1102\u20137.","journal-title":"Br J Cancer"},{"issue":"2","key":"8173_CR56","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11912-020-01003-9","volume":"23","author":"Y Yamada","year":"2021","unstructured":"Yamada Y, Beltran H. Clinical and Biological Features of Neuroendocrine Prostate Cancer. Curr Oncol Rep. 2021;23(2):15.","journal-title":"Curr Oncol Rep"},{"key":"8173_CR57","doi-asserted-by":"publisher","first-page":"8126087","DOI":"10.1155\/2018\/8126087","volume":"2018","author":"P Di Giacinto","year":"2018","unstructured":"Di Giacinto P, Rota F, Rizza L, Campana D, Isidori A, Lania A, Lenzi A, Zuppi P, Baldelli R. Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors. Int J Endocrinol. 2018;2018:8126087.","journal-title":"Int J Endocrinol"},{"key":"8173_CR58","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/978-94-017-7215-0_9","volume":"867","author":"MA Isgr\u00f2","year":"2015","unstructured":"Isgr\u00f2 MA, Bottoni P, Scatena R. Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects. Adv Exp Med Biol. 2015;867:125\u201343.","journal-title":"Adv Exp Med Biol"},{"issue":"17","key":"8173_CR59","doi-asserted-by":"publisher","first-page":"4404","DOI":"10.3390\/cancers15174404","volume":"15","author":"F Dondi","year":"2023","unstructured":"Dondi F, Antonelli A, Suardi N, Guerini AE, Albano D, Lucchini S, et al. PET\/CT and Conventional Imaging for the Assessment of Neuroendocrine Prostate Cancer: A Systematic Review. Cancers (Basel). 2023;15(17):4404. https:\/\/doi.org\/10.3390\/cancers15174404.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"8173_CR60","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1530\/ERC-18-0226","volume":"26","author":"MK Bakht","year":"2018","unstructured":"Bakht MK, Derecichei I, Li Y, Ferraiuolo RM, Dunning M, Oh SW, et al. Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. Endocr Relat Cancer. 2018;26(2):131\u201346.","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"8173_CR61","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/bco2.212","volume":"4","author":"J Chen","year":"2023","unstructured":"Chen J, Shi M, Chuen Choi SY, Wang Y, Lin D, Zeng H, Wang Y. Genomic alterations in neuroendocrine prostate cancer: A systematic review and meta-analysis. BJUI Compass. 2023;4(3):256\u201365.","journal-title":"BJUI Compass"},{"issue":"10","key":"8173_CR62","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41585-021-00490-0","volume":"18","author":"Y Wang","year":"2021","unstructured":"Wang Y, Wang Y, Ci X, Choi SYC, Crea F, Lin D, Wang Y. Molecular events in neuroendocrine prostate cancer development. Nat Rev Urol. 2021;18(10):581\u201396.","journal-title":"Nat Rev Urol"},{"key":"8173_CR63","unstructured":"Lutetium (177Lu.) Vipivotide Tetraxetan (Pluvicto): CADTH Reimbursement Recommendation: Indication: Treatment of adults with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who have received at least one androgen receptor pathway inhibitor and taxane-based chemotherapy [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Mar. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK596311\/"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08173-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08173-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08173-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:30:11Z","timestamp":1793673011000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08173-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":63,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["8173"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08173-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"19 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of IRST IRCCS \/ AVR (CEIIAV), no. 4169\/2017.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Emilio Francesco Giunta: Grants and personal fees from Astellas Pharma, Johnson & Johnson, Novartis. Nicole Brighi: Advisory board or Speaker honoraria from Bristol-Myers Squibb, Gentili Oncology, Johnson & Johnson, Novartis; Travel support from Ipsen, Novartis, Johnson & Johnson. Giuseppe Schepisi: honoraria from Bayer, BMS, Ipsen, Johnson & Johnson. Ugo De Giorgi: personal fees from Amgen, Astellas, AstraZeneca, Bayer, BMS, Eisai, Johnson & Johnson, Ipsen, Merck, MSD, Novartis, Pfizer. Cristian Lolli: Advisory boards or Speaker honoraria from Ipsen, BMS and MSD. The other authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}